摘要
【目的】观察倍他乐克联合小剂量缬沙坦分散片治疗慢性心力衰竭的临床疗效。【方法】选取我院于2014年10月~2020年10月收治的经临床确诊为慢性心力衰竭的患者70例,参照其治疗方案进行分组,对照组(n=35)给予常规治疗,观察组(n=35)加用倍他乐克和小剂量缬沙坦片治疗。统计两组总有效率,检测两组炎性趋化因子、心功能指标也左室射血分数(LVEF)、每搏输出量(SV)页及血清N端脑钠肽前体(NT-proBNP)、肌酸激酶同工酶(CK-MB)、血管紧张素Ⅱ(AngⅡ)的差异,记录两组6分钟步行距离(6MWD)的变化。【结果】观察组疗效高于对照组,有统计学意义(P<0.05)[1]。治疗前,两组炎性趋化因子比较无统计学意义(P>0.05),治疗后,观察组和对照组的趋化因子配体-10(CXCL10)、趋化因子配体-12(CXCL12)、趋化因子配体-16(CXCL16)等炎性趋化因子下降,且观察组炎性趋化因子较对照组低(P<0.05)。治疗前,两组NT-proBNP、CK-MB、AngⅡ比较无统计学意义(P>0.05),治疗后,观察组和对照组的NT-proBNP、CK-MB、AngⅡ下降,且观察组NT-proBNP、CK-MB、AngⅡ较对照组低(P<0.05)。治疗前,两组心功能指标、6MWD比较无统计学意义(P>0.05),治疗后,观察组和对照组的LVEF、SV、6MWD上升,且观察组心功能指标、6MWD较对照组高(P<0.05)。【结论】倍他乐克联合小剂量缬沙坦分散片治疗慢性心力衰竭可延缓心肌重构的发生,降低炎性趋化因子的表达,提高运动耐力。
【Objective】To explore the clinical effect of betaloc combined with low dose valsartan tablets in the treatment of chronic heart failure.【Methods】The 70 patients with chronic heart failure admitted in our hospital from October 2014 to October 2020 were divided into groups according to their treatment plan,and the control group(n=35)was given routine treatment.The observation group(n=35)was treated with betaloc and low dose valsartan tablets.Statistics of total efficiency in both groups,The difference of inflammatory chemokines,cardiac function index[left ventricular ejection fraction(LVEF),stroke output(SV)]and serum N end brain natriuretic peptide precursor(NT-proBNP),creatine kinase isoenzyme(CK-MB),angiotensinⅡ(AngⅡ)were detected,Changes in 6-minute walking distance(6 MWD)were recorded in two groups.【Results】Compared with the control group,the curative effect of the observation group was statistically significant(P<0.05).Before treatment,there was no significant difference between the two groups(P>0.05),the inflammatory chemokines such as chemokine ligand-10(CXCL10),chemokine ligand-12(CXCL12),chemokine ligand-16(CXCL16)in the observation group and control group decreased after treatment,and the inflammatory chemokines in the observation group were lower than those in the control group(P<0.05).There was no significant NT-proBNP、CK-MB、AngⅡbetween the two groups before treatment(P>0.05),The NT-proBNP、CK-MB、AngⅡof observation group and control group decreased after treatment,and the NT-proBNP、CK-MB、AngⅡof observation group was lower than that of control group(P<0.05).There was no significant difference in cardiac function index,6 MWD between the two groups before treatment(P>0.05),The LVEF、SV、6MWD of observation group and control group increased after treatment,and the cardiac function index and 6 MWD of observation group were higher than those of control group(P<0.05).【Conclusion】Betaloc combined with low dose valsartan tablets in the treatment of chronic heart failure can delay the occurrence of myocardial remodeling,reduce the expression of inflammatory chemokines,and improve exercise endurance.
作者
符媛
高运安
文晓晶
FU Yuan;GAO Yun-an;WEN Xiao-jing(Department of pharmacy,Dongfang Hospital of Traditional Chinese Medicine,Hainan 572600,China)
出处
《武警后勤学院学报（医学版）》
CAS
2021年第6期4-8,共5页
Journal of Logistics University of PAP（Medical Sciences）
